Nanoscopy reveals heparan sulfate clusters as docking sites for SARS-CoV-2 attachment and entry
eLife · 2026
DOI: 10.7554/elife.108925 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2026. Verfasst von Sue Han und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Neurological Disorders and Stroke, Bethesda, United States. Hauptthemen laut MEDLINE: Heparan Sulfate, SARS-CoV-2, Virus Internalization, Virus Attachment. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: National Institute of Allergy and Infectious Diseases, NINDS NIH HHS, NIBIB NIH HHS.
Abstract (Originalsprache)
Virus entry is thought to involve binding a unique receptor for cell attachment and cytosolic entry. For SARS-CoV-2 underlying the COVID-19 pandemic, angiotensin-converting enzyme 2 (ACE2) is widely considered the receptor for cell-surface attachment and subsequent cell entry. Using advanced light microscopy to resolve individual virions and receptors, we found instead that heparan sulfate (HS), not ACE2, mediates SARS-CoV-2 cell-surface attachment, and subsequent endocytosis. ACE2 functions only downstream of HS to enable viral genome expression. Instead of binding single HS molecules that electrostatically interact with viral surface proteins weakly, SARS-CoV-2 binds clusters of ~6–137 HS molecules projecting 60–410 nm above the plasma membrane. These tall, HS-rich clusters, present at about one per 6 μm², act as docking sites for viral attachment. Blocking HS binding with the clinically used HS-binding agent pixantrone strongly inhibited an authentic pathogen, the SARS-CoV-2 Omicron JN.1 subvariant, from attaching to and infecting human airway cells. This work establishes a revised entry paradigm in which HS clusters mediate SARS-CoV-2 attachment and endocytosis, with ACE2 acting downstream, thereby identifying HS interactions as a key anti-COVID-19 strategy. This paradigm and its therapeutic implications may apply broadly beyond COVID-19 because, analogous to SARS-CoV-2, HS binds many other viruses but is only considered an attachment regulator.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Institute of Neurological Disorders and Stroke, Bethesda, United States.
- Cellular Biology Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States.
- Abberior Instruments America LLC, Bethesda, United States.
- Intramural Research Program, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, United States.
ORCID-Profile: Sue Han, Xin Wang, Tiansheng Li, Ivan Kosik, Chung Yu Chan, Alberto Domingo López-Muñoz, Zhixiong Wang, Albert J Jin, Jonathan W Yewdell, Ling-Gang Wu
Förderung
- National Institute of Allergy and Infectious Diseases
- NINDS NIH HHS
- NIBIB NIH HHS
- Intramural NIH HHS
- National Institute of Neurological Disorders and Stroke
- National Institute of Biomedical Imaging and Bioengineering
Zitieren
APA
Han, S., Wang, X., Li, T., Mohseni, A., Kosik, I., Chan, C. Y., López-Muñoz, A. D., Matthias, J., Suddaby, R., Wang, Z., Jin, A. J., Wurm, C. A., Yewdell, J. W., & Wu, L. G. (2026). Nanoscopy reveals heparan sulfate clusters as docking sites for SARS-CoV-2 attachment and entry. eLife. https://doi.org/10.7554/elife.108925
Vancouver
Han S, Wang X, Li T, Mohseni A, Kosik I, Chan CY, et al. Nanoscopy reveals heparan sulfate clusters as docking sites for SARS-CoV-2 attachment and entry. eLife. 2026. doi:10.7554/elife.108925
BibTeX
@article{Han2026,
author = {Han, Sue and Wang, Xin and Li, Tiansheng and Mohseni, Ammar and Kosik, Ivan and Chan, Chung Yu and López-Muñoz, Alberto Domingo and Matthias, Jessica and Suddaby, Reid and Wang, Zhixiong and Jin, Albert J and Wurm, Christian A and Yewdell, Jonathan W and Wu, Ling-Gang},
title = {Nanoscopy reveals heparan sulfate clusters as docking sites for SARS-CoV-2 attachment and entry},
journal = {eLife},
year = {2026},
doi = {10.7554/elife.108925}
}
EUVIMED